Cabaletta Bio, Inc.

Cabaletta does not currently sell commercial products, so its near-term 'customers' are primarily clinical trial sites, investigators, and patients enrolled in its studies. If approved, the eventual buyers would be specialty physicians, hospitals, and treatment centers managing severe autoimmune diseases that require advanced immunotherapy. Payers and health systems would also be important decision-makers because these therapies are likely to be high-cost, specialized treatments. The company’s business model depends on convincing clinicians that its targeted cell therapies can offer meaningful benefit versus existing immunosuppressive or biologic options.

Cabaletta’s strategy is to advance rese-cel through multiple RESET clinical trials and build enough clinical evidence to support regulatory approval in autoimmune diseases. A major priority is manufacturing readiness, including transfer of an improved process to Lonza and evaluation of multiple scale-up options such as additional CDMOs, leased facilities, or an owned manufacturing site. The company is also broadening the pipeline across several autoimmune indications, which can increase the value of the platform if one program validates the approach. Because it has no product revenue, capital preservation and access to financing remain central to executing the development plan.